Skip to main content
. 2015 Nov 2;7(1):1055–1065. doi: 10.18632/oncotarget.6274

Table 3. Time-To-Treatment univariate and multivariate analyses.

Time to treatment
Univariate analysis Multivariate analysis
HR [95%CI] p value AHR [95%CI] p value
AGE
[19-55] 1 (reference) <0.001
[56-65] 0.72 [0.6-0.87]
[66-74] 0.6 [0.51-0.72]
[75-92] 0.73 [0.61-0.88]
GENDER
Female 1 (reference) <0.001
Male 0.46 [0.4-0.53]
TUMOUR SITE
Breast 1 (reference) <0.001 1 (reference) <0.001
Prostate 0.32 [0.26-0.39] 0.32 [0.27-0.39]
Lung 0.76 [0.63-0.93] 0.75 [0.62-0.92]
Sarcoma 0.7 [0-5.1] 0.7 [0.49-0.99]
Colorectal 0.81 [0.66-0.99] 0.81 [0.66-0.99]
ECOG PS
0 0.56 [0.36-0.86] 0.046
1 0.53[0.34-0.83]
2 0.65 [0.4-1.06]
>2 1 (reference)
QUINTILE EDI
1 1 (reference) 0.324 1 (reference) 0.982
2 0.84 [0.67-1.05] 0.98 [0.78-1.22]
3 0.98 [0.78-1.23] 1.04 [0.82-1.31]
4 0.99 [0.79-1.24] 0.99 [0.79-1.2]
5 1.0023 [0.81-1.24] 0.98 [0.79-1.21]
T staging
1 1 (reference) <0.001
2 0.81 [0.7-0.95]
3 0.84 [0.7-1.02]
4 1.54 [1.2-2]
N staging
0 1 (reference) <0.001
1 1.33 [1.1-1.6]
2 1.5 [1.2-1.8]
3 1.2 [0.8-1.8]
M status
0 1 (reference) <0.001
1 1.58 [1.34-1.87]